HIV Vaccine Research and Development
Document text
Principal Investigator: JULIE AKE Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES Fiscal Year: 2022 Award: $17,792,120 Funding agency: National Institute of Allergy and Infectious Diseases The NIAID Division of AIDS and the U.S. Military HIV Research Program (MHRP), Walter Reed Army Institute of Research (WRAIR), U.S. Army Medical Research and Development Command (MRDC) remain committed to the common objective of developing a safe and effective vaccine for HIV/AIDS. The Agencies recognize the potential utility of an HIV/AIDS vaccine in stopping the global HIV/AIDS epidemic and the need to conduct and support basic science, preclinical development, and both vaccine and non-vaccine clinical research in developing countries where the epidemic is most prevalent. This Agreement covers the following scope of work: • design and construction of candidate HIV vaccines • pre-clinical research and development, including evaluation of candidate vaccines • pilot lot production • clinical site development including cohort characterization • phase 1-3 human clinical safety, immunogenicity, and efficacy testing • other clinical and epidemiological research studies that support HIV vaccine development Terms: <AIDS><AIDS Virus><AIDS/HIV><AIDS/HIV problem><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immuno-Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Acquired Immunologic Deficiency Syndrome><Acute><Agreement><Armed Forces Personnel><Basic Research><Basic Science><Clinical><Clinical Research><Clinical Study><Cohort Studies><Concurrent Studies><Critical Paths><Critical Pathways><Data><Developing Countries><Developing Nations><Development><Development and Research><Disease remission><Epidemic><Epidemiologic Research><Epidemiologic Studies><Epidemiological Studies><Epidemiology Research><Evaluation><HIV><HIV Infections><HIV vaccine><HIV/AIDS><HIV/AIDS Vaccines><HIV/AIDS problem><HTLV-III Infections><HTLV-III-LAV Infections><Human><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Infections><Immunization><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunostimulation><Incidence><International><Intervention><Intervention Strategies><LAV-HTLV-III><Length><Less-Developed Countries><Less-Developed Nations><Lymphadenopathy-Associated Virus><Medical Research><Military><Military Personnel><Modern Man><Monitor><NIAID><National Institute of Allergy and Infectious Disease><Phase><Production><R & D><R&D><RNA vaccine><RNA-based vaccine><Regimen><Remission><Research><Research Institute><Safety><Sampling><Site><Specimen Handling><Specimen Processing><Thailand><Third-World Countries><Third-World Nations><Under-Developed Countries><Under-Developed Nations><Vaccines><Virus-HIV><Work><clinical research site><clinical site><cohort><depository><design and construct><design and construction><develop a vaccine><develop vaccines><developing country><developing nation><development of a vaccine><developmental><efficacy testing><epidemiologic investigation><epidemiology study><human immunodeficiency virus vaccine><immunogenicity><interventional strategy><mRNA vaccine><mRNA-based vaccine><military population><operation><pilot lot production><pre-clinical development><pre-clinical research><preclinical development><preclinical research><programs><repository><research and development><research study><vaccine candidate><vaccine development>